Navigation Links
AngioGenex Reviews 2008 Achievements and Sets Goals for 2009
Date:11/25/2008

NEW YORK,Nov. 25 /PRNewswire-FirstCall/ -- AngioGenex, Inc. (OTC Bulletin Board: AGGX) is a New York-based biotechnology company that leads in targeting Id genes and proteins for the discovery and development of anti-angiogenic drugs to treat cancer. Today the Company announced achievement of its 2008 objectives and its key business goals for 2009.

AngioGenex accomplished a number of important milestones that it set for itself in 2008. In the Research and Development area, the Company completed key pilot studies on novel anti-angiogenic drugs and filed US and foreign patent applications for these agents. A major goal of 2008 was to complete in vivo studies of its lead small molecule drug candidate (AGX51) that would establish the ability of the agent to reduce angiogenesis and to block the growth and metastasis of tumors. According to Dr. Garland, "the data from those studies clearly met this goal and AGX51 has the potential of being the first orally active anti-angiogenic drug that acts by a mechanism not associated with VEGF, the target of Avastin(R), Genentech's blockbuster anti-cancer drug." Moreover, the results demonstrated that mice tolerate AGX51 without any apparent side effects.

In the corporate area, Dr. Richard Salvador, the former global head of Preclinical Development at Hoffmann La Roche, Inc. became Chairman of the Board of Directors and Dr. Garland, who has led the company's drug discovery and development effort, became the CEO.

AngioGenex took important steps to satisfy its near term corporate finance needs and to meet its future capital formation goals. The Company raised a modest amount of equity capital from new and existing shareholders to fund the AGX51 pilot studies, and it retained Griffin Securities LLC, an investment banking firm specializing in early stage biotechnology companies. Working with Griffin, the Company has identified a number of potential corporate pa
'/>"/>

SOURCE AngioGenex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. William Garland Joins AngioGenexs New Board of Directors
2. AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs
3. CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market
4. CBDM.T, The Market and Business Intelligence Company Reviews The Biomanufacturing Market
5. Pharma Opinions Site Reviews the Breakthrough Drugs of Pharmaceutical Companies
6. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
7. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
8. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
9. Millennium Over-Delivers on 2007 Goals and Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... -- New open access, ... serving the international surgical community ... technical, and medical information products and services, today announced ... Surgery Open ( IJS Open ), a ... This peer-reviewed, online-only journal will make significant contributions to ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... On August ... inviting a diverse selection of entrepreneurs from across the United States to talk about ... Richman is honored to be chosen to be among the attendees. , One of ...
(Date:8/3/2015)... 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... the second quarter 2015 on Monday, August 10, 2015 ... Torley , president and chief executive officer, will lead ... release financial results for the second quarter 2015. ... "Investors" section of Halozyme,s corporate website and a recording ...
(Date:8/3/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic and Dental sectors of healthcare, announced today that ... Canaccord|Genuity Growth Conference in Boston, Massachusetts ... William C. Taylor , President and COO, and ...
Breaking Biology Technology:Elsevier Announces the Launch of International Journal of Surgery Open 2Elsevier Announces the Launch of International Journal of Surgery Open 3Elsevier Announces the Launch of International Journal of Surgery Open 4White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2
... (Nasdaq:,SIAL) announced today the global release of ... researchers to reproducibly,interrogate gene function, via siRNA ... not been considered amenable to conventional lipid-based,siRNA ... reagents exhibit a number,of drawbacks, including high ...
... DIEGO, Oct. 18 Volcano Corporation,(Nasdaq: VOLC ) ... shares of its common stock at a price of ... by Volcano. Volcano has granted the,underwriters a 30-day option ... common stock to cover over-allotments, if any. The offering,is ...
... Oct. 17 AMICAS, Inc. (Nasdaq: AMCS ),a ... today announced it will present to and meet with ... being held in New,York. (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ... -- Presentation begins promptly at 10:20 a.m. (Eastern ...
Cached Biology Technology:Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types 2Volcano Corporation Announces Pricing of Common Stock Offering 2
(Date:7/21/2015)... OXFORD, Connecticut , July 21, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet, announces that it has ... Tokenization System and Method. This ... that not only authorizes an account, but also ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... elderly people from benefiting equally from exercise, no matter ... published in today's (Aug. 10) Journal of the American ... who exercised stayed healthier than their couch potato peers, ... most from physical activity, said Marco Pahor, M.D., director ...
... a single gene, Nrf2, plays a critical role in ... by Shyam Biswal, PhD, at the Johns Hopkins Bloomberg ... exacerbated allergen-mediated asthma in mice models. The study’s findings, ... Journal of Experimental Medicine, may hold therapeutic potential for ...
... future hopes for human applications , Israeli scientists report ... successfully transplanted whole frozen and thawed ovaries in sheep, ... the laboratory into early embryonic development. , Follow-up tests ... which oocytes were recovered were still functioning normally three ...
Cached Biology News:Exercise aside, genes may ultimately dictate seniors' mobility 2Exercise aside, genes may ultimately dictate seniors' mobility 3Researchers Discover Gene That Determines Asthma Susceptibility By Regulating Inflammation 2Israeli scientists successfully transplant frozen-thawed ovaries in sheep 2Israeli scientists successfully transplant frozen-thawed ovaries in sheep 3
... I (RNase-free) (E.C. 3.1.21.1) is a nonspecific ... chromatin. It functions by hydrolyzing phosphodiester linkages, ... and a 3'-hydroxyl group. Ambion's RNase-free DNase ... and is recommended to degrade DNA in ...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
... Perhaps sheer in-house demand is causing ... want your precious antibody. This can cause ... • Receive royalties for your hard ... and let us build it up and ...
... (rat) - Diluted Antiserum for RIA, Host: ... U-23 (rat) Immunology Products, Host: Rabbit ... our corresponding peptide and 1 ... Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
Biology Products: